Powered by

Lilly's Trulicity shows superiority in reducing CV events in type 2 diabetes

Nov 06, 2018 - Marketline Newswire

Global pharmaceutical company Eli Lilly has announced its Trulicity (dulaglutide) has demonstrated superiority to placebo combined with standard of care in reducing the number of major adverse cardiovascular (CV) events (MACE) in patients with type 2 diabetes.

The drug also showed a reduction in cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in the REWIND trial.Lilly claims that this study differs from previous trial since of the 9,901 participants from 24 count...